TLPH Profile
Talphera, Inc., a specialized pharmaceutical company, is dedicated to developing and commercializing advanced therapeutic solutions designed for use in medically supervised environments. The company is at the forefront of creating innovative treatments with a focus on enhancing patient outcomes and addressing unmet medical needs.
Talphera's leading product candidate is Niyad, a lyophilized formulation of nafamostat, which is currently being evaluated under an investigational device exemption as an anticoagulant for extracorporeal circuits. This formulation is intended to improve anticoagulation during complex medical procedures involving extracorporeal blood circulation, potentially offering significant benefits in settings such as dialysis and certain surgical interventions.
In addition to Niyad, Talphera is advancing several other key products. LTX-608 is being developed as a multi-faceted therapeutic with potential anti-inflammatory and antiviral properties, aimed at treating a range of conditions including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. The company is also working on Fedsyra, a pre-filled ephedrine syringe designed for rapid administration in critical situations, and PFS-02, a pre-filled phenylephrine syringe for managing acute hypotension.
Founded in 2005 and headquartered in San Mateo, California, Talphera, Inc. was previously known as AcelRx Pharmaceuticals, Inc., and rebranded in January 2024 to better reflect its evolving focus and portfolio. The company's commitment to developing high-impact therapies is underscored by its innovative approach and dedication to improving patient care through medically supervised treatments.
|
